I hope ENTA can secure one or two partnerships next year to demonstrate its potential. With several assets already awaiting partnerships to advance, RSV is now being added to the list. This is a key concern for many investors. While ENTA excels at developing drugs, its ability to secure the partnerships needed to bring those drugs to market seems underwhelming.
I strongly believe that securing a solid RSV partnership could lead the market to revalue many of their assets with positive rather than negative value. A $30 share price wouldn’t be out of the question and might even be conservative, depending on the deal terms.
Market Data 
Markets 
AI
